The ASCO Post

The ASCO Post News and views from the world of clinical oncology and hematology

THE ASCO POST delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO's annual meeting and regional symposia. Additionally, this newspaper-style publication provides readers with important summaries of evidence-based clinical literature from both general and specialty journals (fully sourced with links to original reports); notable research, data, and liter

ature with application in the clinic, including cost considerations/implications; columns from ASCO's membership with perspective on developments in oncology, quality cancer care, technology, electronic health records, and expert opinion on the state and economics of cancer care.

New findings in advanced squamous non–small cell lung cancer may signal an important advance for patients with poor outc...
06/04/2026

New findings in advanced squamous non–small cell lung cancer may signal an important advance for patients with poor outcomes.

“This is one of very few studies in advanced squamous [NSCLC] that has shown median survival beyond 2 years,” explained lead author Shun Lu, PhD, of Shanghai Chest Hospital, Jiao Tong University School of Medicine.

The phase III HARMONi-6 trial, presented at the Plenary Session during , showed an overall survival in patients with advanced squamous NSCLC from treatment with the investigational bispecific antibody ivonescimab combined with chemotherapy.

Key findings included:
• Reduced risk of death
• Benefits observed across PD-L1 expression subgroups

• Comparable safety profile

https://ascopost.com/news/june-2026/overall-survival-benefit-with-ivonescimab-plus-chemotherapy-in-advanced-squamous-nsclc/

The future of lung cancer treatment is increasingly defined by molecular precision. New data from the phase III LIBRETTO...
06/03/2026

The future of lung cancer treatment is increasingly defined by molecular precision.

New data from the phase III LIBRETTO-432 study show that adjuvant selpercatinib significantly improved event-free survival in patients with RET-positive early-stage NSCLC (HR = 0.165), underscoring the growing impact of biomarker-driven treatment strategies beyond the metastatic setting.

Presented by Jonathan Goldman, MD of UCLA Health during the Plenary Session of

https://ascopost.com/news/june-2026/adjuvant-selpercatinib-improves-event-free-survival-in-ret-positive-early-stage-nsclc/

: Cancer research is becoming increasingly granular and increasingly intelligent. A new article from ASCO AI in Oncolog...
06/02/2026

: Cancer research is becoming increasingly granular and increasingly intelligent.

A new article from ASCO AI in Oncology explores how single-cell resolution survival modeling could help uncover deeper biological insights across cancer types, highlighting the growing role of AI-driven computational approaches in oncology.

The intersection of AI, genomics, and oncology continues to evolve rapidly.

Learn more: https://ascoai.org/articles/2026/05/bringing-cancer-survival-modeling-to-singlecell-resolution/

Could the time-of-day immunotherapy is administered influence outcomes in advanced cancer? A new meta-analysis suggests ...
06/01/2026

Could the time-of-day immunotherapy is administered influence outcomes in advanced cancer?

A new meta-analysis suggests that earlier administration times for immune checkpoint inhibitors may be associated with improved survival outcomes across several tumor types.

An intriguing example of how circadian biology may shape future cancer treatment strategies.

Read more: https://ascopost.com/news/may-2026/does-the-timing-of-immunotherapy-administration-affect-outcomes-in-advanced-cancers/

As cancer survivorship continues to grow, so does the importance of personalized follow-up care. A new study suggests th...
05/29/2026

As cancer survivorship continues to grow, so does the importance of personalized follow-up care.

A new study suggests that retrospective genetic testing programs may help uncover inherited cancer risk in survivors who were never previously tested.

An important conversation around survivorship, prevention, and long-term care planning.

Presented by Clare Turnbull, MD, PhD of Institute of Cancer Research at

Learn more: https://ascopost.com/news/may-2026/study-examines-genetic-testing-to-inform-follow-up-care-for-cancer-survivors/

Momentum continues to build for immunotherapy in GI cancers. New research evaluating toripalimab alongside perioperative...
05/28/2026

Momentum continues to build for immunotherapy in GI cancers.

New research evaluating toripalimab alongside perioperative chemotherapy in patients with gastric and gastroesophageal junction cancer reflects a broader shift toward integrating immunotherapy into earlier-stage treatment strategies.

Study by Nie et al | Published in Journal of Clinical Oncology from

Explore the findings: https://ascopost.com/news/may-2026/addition-of-toripalimab-to-perioperative-chemotherapy-in-locally-advanced-gastric-or-gastroesophageal-junction-cancer/

🖥️ : AI is becoming more prominent in healthcare innovation. The U.S. Food and Drug Administration upgraded internal AI...
05/27/2026

🖥️ : AI is becoming more prominent in healthcare innovation.

The U.S. Food and Drug Administration upgraded internal AI tool highlights how quickly artificial intelligence is becoming part of the infrastructure behind research, regulation, and clinical advancement.

For oncology, that could mean faster insights, more efficient review processes, and accelerated innovation pipelines.

Learn more: https://ascoai.org/articles/2026/05/fda-upgrades-internal-ai-tool/

As targeted therapies continue to expand in thyroid cancer, updated clinical guidance becomes increasingly important. A ...
05/25/2026

As targeted therapies continue to expand in thyroid cancer, updated clinical guidance becomes increasingly important.

A new ASCO guideline helps address gaps in navigating emerging therapies and treatment strategies in thyroid cancer care.

An important resource for clinicians working to keep pace with a rapidly changing treatment landscape.

Nabil F. Saba, MD, of Emory University University and Beth M. Beadle, MD, of Stanford University, co-chaired the Expert Panel that produced the new guideline.

Read the guidelines: https://ascopost.com/issues/may-10-2026/new-asco-guideline-fills-gap-in-guidance-on-rapidly-evolving-treatment-options-in-thyroid-cancer/

Address

Huntington, NY

Website

Alerts

Be the first to know and let us send you an email when The ASCO Post posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category